A phase II study evaluating the safety and efficacy of ARGX-113, a human IgG1-derived Fc fragments binding to FcRn in patients with PV and PF is currently ongoing (NCT03334058) (287). The gene discussed is FCGRT; the disease is acquired polycythemia vera.